BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 31602268)

  • 1. Targeting immunotherapy for bladder cancer by using anti-CD3 × CD155 bispecific antibody.
    Ma W; Ma J; Lei T; Zhao M; Zhang M
    J Cancer; 2019; 10(21):5153-5161. PubMed ID: 31602268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancer.
    Zhao H; Ma J; Lei T; Ma W; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):810-817. PubMed ID: 30374653
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting immunotherapy for bladder cancer using anti-CD3× B7-H3 bispecific antibody.
    Ma W; Ma J; Ma P; Lei T; Zhao M; Zhang M
    Cancer Med; 2018 Oct; 7(10):5167-5177. PubMed ID: 30253078
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting bladder cancer using activated T cells armed with bispecific antibodies.
    Ma J; Ge J; Xue X; Xiu W; Ma P; Sun X; Zhang M
    Oncol Rep; 2018 Mar; 39(3):1245-1252. PubMed ID: 29328392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bispecific anti-CD3×anti-CD155 antibody mediates T-cell immunotherapy in human haematologic malignancies.
    Ma L; Ma J; Sun X; Liu H
    Invest New Drugs; 2023 Jun; 41(3):522-531. PubMed ID: 37198354
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bispecific anti-CD3 x anti-HER2 antibody mediates T cell cytolytic activity to HER2-positive colorectal cancer in vitro and in vivo.
    Han H; Ma J; Zhang K; Li W; Liu C; Zhang Y; Zhang G; Ma P; Wang L; Zhang G; Tao H; Gao B
    Int J Oncol; 2014 Dec; 45(6):2446-54. PubMed ID: 25242665
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bispecific anti-CD3 x anti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo.
    Ma J; Shang T; Ma P; Sun X; Zhao J; Sun X; Zhang M
    Invest New Drugs; 2019 Oct; 37(5):1036-1043. PubMed ID: 30706335
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting cytomegalovirus-infected cells using T cells armed with anti-CD3 × anti-CMV bispecific antibody.
    Lum LG; Ramesh M; Thakur A; Mitra S; Deol A; Uberti JP; Pellett PE
    Biol Blood Marrow Transplant; 2012 Jul; 18(7):1012-22. PubMed ID: 22313635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human T cells armed with Her2/neu bispecific antibodies divide, are cytotoxic, and secrete cytokines with repeated stimulation.
    Grabert RC; Cousens LP; Smith JA; Olson S; Gall J; Young WB; Davol PA; Lum LG
    Clin Cancer Res; 2006 Jan; 12(2):569-76. PubMed ID: 16428502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD3 x EGFR bispecific antibody redirects cytokine-induced killer cells to glioblastoma in vitro and in vivo.
    Ma P; He Q; Li W; Li X; Han H; Jin M; Liu C; Tao H; Ma J; Gao B
    Oncol Rep; 2015 Nov; 34(5):2567-75. PubMed ID: 26323605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting.
    Sun X; Yu Y; Ma L; Xue X; Gao Z; Ma J; Zhang M
    Invest New Drugs; 2020 Jun; 38(3):722-732. PubMed ID: 31267380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B7-H3 as a promising target for cytotoxicity T cell in human cancer therapy.
    Ma J; Ma P; Zhao C; Xue X; Han H; Liu C; Tao H; Xiu W; Cai J; Zhang M
    Oncotarget; 2016 May; 7(20):29480-91. PubMed ID: 27121051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD3 x anti-epidermal growth factor receptor (EGFR) bispecific antibody redirects T-cell cytolytic activity to EGFR-positive cancers in vitro and in an animal model.
    Reusch U; Sundaram M; Davol PA; Olson SD; Davis JB; Demel K; Nissim J; Rathore R; Liu PY; Lum LG
    Clin Cancer Res; 2006 Jan; 12(1):183-90. PubMed ID: 16397041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.
    Sun X; Zhao J; Ma L; Sun X; Ge J; Yu Y; Ma J; Zhang M
    Invest New Drugs; 2021 Feb; 39(1):24-33. PubMed ID: 32770284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.
    Gall JM; Davol PA; Grabert RC; Deaver M; Lum LG
    Exp Hematol; 2005 Apr; 33(4):452-9. PubMed ID: 15781336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-CS1 × Anti-CD3 Bispecific Antibody (BiAb)-Armed Anti-CD3 Activated T Cells (CS1-BATs) Kill CS1
    Lum LG; Thakur A; Elhakiem A; Alameer L; Dinning E; Huang M
    Front Oncol; 2020; 10():544. PubMed ID: 32432032
    [No Abstract]   [Full Text] [Related]  

  • 18. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-CD3/anti-CD28 bead stimulation overcomes CD3 unresponsiveness in patients with head and neck squamous cell carcinoma.
    Shibuya TY; Wei WZ; Zormeier M; Ensley J; Sakr W; Mathog RH; Meleca RJ; Yoo GH; June CH; Levine BL; Lum LG
    Arch Otolaryngol Head Neck Surg; 2000 Apr; 126(4):473-9. PubMed ID: 10772300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness.
    Thakur A; Ung J; Tomaszewski EN; Schienschang A; LaBrie TM; Schalk DL; Lum LG
    Oncoimmunology; 2021 Jun; 10(1):1930883. PubMed ID: 34123574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.